Botulinum toxin treatment of cephalalgia alopecia increases substance P and calcitonin gene-related peptide-containing cutaneous nerves in scalp.
Cutrer
F M
FM
Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA. cutrer.michael@mayo.edu
Sandroni
P
P
Wendelschafer-Crabb
G
G
D000505:Alopecia / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D015740:Calcitonin Gene-Related Peptide / Q000187:drug effects* / Q000378:metabolism; D015550:Cell Degranulation / Q000187:drug effects; D005260:Female; D018859:Hair Follicle / Q000187:drug effects / Q000294:innervation / Q000473:pathology; D006261:Headache / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D008407:Mast Cells / Q000187:drug effects; D018613:Microscopy, Confocal; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D012535:Scalp / Q000187:drug effects / Q000294:innervation / Q000473:pathology; D013373:Substance P / Q000187:drug effects* / Q000378:metabolism
D009465:Neuromuscular Agents; D013373:Substance P; D019274:Botulinum Toxins, Type A; D015740:Calcitonin Gene-Related Peptide